News

April 14, 2020

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD

April 1, 2020

Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™

February 18, 2020

Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent

February 11, 2020

Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN

January 28, 2020

Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead

January 22, 2020

Kannalife, Inc. Issues Update on Intellectual Property and Patent Estate

January 14, 2020

Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain

January 7, 2020

Kannalife Secures New INCI Name for its Prospective Anti-Inflammatory and Antioxidant Ingredient Atopidine™

December 18, 2019

CBD: Perils, Promise and Development for Neuropathic Pain

December 11, 2019

Kannalife, Inc. Announces Filing of U.S. Patent 62/934,861 – Functionalized 1, 3 Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders

December 9, 2019

Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol “KLFE”

September 26, 2019

Quick Links Section

September 25, 2019

Douglas Brenneman, PhD

September 25, 2019

Mark McDonnell, PhD

September 25, 2019

Daniel Richman, MD

September 25, 2019

Timothy Scott, PhD

September 25, 2019

Blake Schroeder

September 25, 2019

Robert Malasek

September 25, 2019

Mark Corrao

September 25, 2019

Thoma Kikis

Get the Latest in Neuropathix News

Subscribe